Lipid-lowering efficacy, safety, and costs of a large-scale therapeutic statin formulary conversion program

Pharmacotherapy

Volumn 21, Issue 9 I, 2001, Pages 1130-1139

  Taylor, A J ^a   Grace, K ^a   Swiecki, J ^a   Hyatt, R ^a   Gibbs, H ^a   Sheikh, M ^a   O'Malley, P G ^a   Lowenthal, S P ^a   West, M ^a   Spain, J ^a   Maneval, K ^a   Jones, D L ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; CERIVASTATIN; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADULT; AGED; ALGORITHM; AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DOSE RESPONSE; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; LIPID LIVER LEVEL; MAJOR CLINICAL STUDY; MALE; MYOSITIS; PROSPECTIVE STUDY; SHORT SURVEY; TREATMENT INDICATION; TREATMENT PLANNING;

EID: 0034861518     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.21.13.1130.34616     Document Type: Short Survey

References (22)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S)
2. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas coronary atherosclerosis prevention study
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: The longterm intervention with pravastatin in ischaemic disease (LIPID)
4. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts
5. Effect of simvastatin on coronary atheroma: The multicentre anti-atheroma study (MAAS)
6. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and recurrent events trial investigators
7. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland coronary prevention study group
8. Therapeutic options and cost considerations in the treatment of ischemic heart disease
9. Increased thrombotic vascular events after change of statin
10. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar?
11. Effect of itraconazole on cerivastatin pharmacokinetics
12. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II)
13. Accurate direct determination of low-density lipoprotein cholesterol using an immunoseparation reagent and enzymatic cholesterol assay
14. Conversion of patients from simvastatin to lovastatin in an outpatient pharmacy clinic
15. Impact of therapeutic interchange from pravastatin to lovastatin in a Veterans Affairs Medical Center
16. Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: The pivotal placebo-controlled clinical trial: Cerivastatin study group
17. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin
18. Clinical efficacy and safety of cerivastatin: Summary of pivotal phase IIb/III studies
19. Cerivastatin in primary hyperlipidemia: A multicenter analysis of efficacy and safety
20. Clinical positioning of HMG-CoA reductase inhibitors in lipid management protocols
21. Comparative dose efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
22. Clinical pharmacokinetics of cerivastatin